Literature DB >> 1729064

Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease.

P Thomas1, J A Pugsley, J H Stewart.   

Abstract

To investigate the efficacy of bronchodilators in patients with irreversible chronic obstructive pulmonary disease (COPD), we conducted a double-blind, randomized, four-phase, crossover comparison between placebo, oral theophylline, inhaled salbutamol, and a combination of both drugs in 12 patients with stable COPD (mean age, 63 years) whose increase in forced expiratory volume in 1 s (FEV1) was less than or equal to 15 percent following 200 micrograms of inhaled salbutamol. Patients received two weeks of therapy with each of the test regimens. Both theophylline and salbutamol resulted in statistically significant improvement in FEV1, forced vital capacity (FVC), slow vital capacity (SVC), residual volume (RV), airway resistance (Raw), and maximum expiratory flow rate at 50 percent of vital capacity (V50). In most instances, there were no significant differences between theophylline and salbutamol. Combination therapy produced significantly greater improvement in FEV1, FVC, V50, Raw, and RV than either agent alone. The two drugs interacted in an additive fashion. Neither of the drugs, used singly, significantly reduced the severity or incidence of symptoms. The reduction in dyspnea and wheeze during combination therapy approached statistical significance (p = 0.06) and patient preference was significantly in favor of the combination regimen. None of the active treatments produced significantly more side effects than placebo. We conclude that theophylline and inhaled salbutamol produce significant, and approximately equal, improvement in pulmonary function in patients traditionally classified as suffering from "irreversible" COPD. The combination of theophylline and inhaled salbutamol generally results in additional improvement over that obtained with either drug used alone and this improvement is reflected by reduced symptomatology and treatment preference.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729064     DOI: 10.1378/chest.101.1.160

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

Authors:  B Jarvis; A Markham
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.

Authors:  Apar Jindal; V Viswambhar; Arun Babu V
Journal:  J Clin Diagn Res       Date:  2015-02-01

4.  What role for theophylline?

Authors:  J W Jenne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

5.  N-acetylcysteine instead of theophylline in patients with COPD who are candidates for elective off-pump CABG surgery: Is it possible in cardiovascular surgery unit?

Authors:  Seyed Jalil Mirhosseini; Seyed Khalil Forouzannia; Marjan Nasirian; Sadegh Ali-Hassan-Sayegh
Journal:  Saudi J Anaesth       Date:  2013-04

6.  A meta-analysis on the efficacy of oral theophylline in patients with stable COPD.

Authors:  Néstor A Molfino; Peter Zhang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

7.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials.

Authors:  R Graham Barr; Brian H Rowe; Carlos A Camargo
Journal:  BMJ       Date:  2003-09-20

Review 8.  Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.

Authors:  Preeti Gupta; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.